Heartflow Files Patent Infringement Lawsuit Against Cleerly

Rhea-AI Summary

News Market Reaction – HTFL

+1.78%

6 alerts

+1.78% Session close to close

+13.4% Peak in 28 hr 10 min

$2.52B Market Cap

0.3x Rel. Volume

In the Apr 13 session, HTFL gained 1.78%, reflecting a mild positive market reaction. Argus tracked a peak move of +13.4% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on Heartflow’s attempt to enforce its intellectual property through a pate...

Analysis

This announcement centers on Heartflow’s attempt to enforce its intellectual property through a patent infringement lawsuit covering 6 patents with priority dates from 2012–2018. It emphasizes a platform used in 600,000+ patients and an IP portfolio of over 600 patents. Investors may contextualize this against recent growth-focused filings, ongoing insider Net Selling, and previous news-driven moves when assessing how legal outcomes could intersect with the company’s broader strategy.

Key Figures

Patents alleged infringed: 6 patents Patent priority window: 2012–2018 Patients impacted: over 600,000 patients +2 more

5 metrics

Patents alleged infringed 6 patents Cleerly’s Ischemia, Plaque Analysis, and Compare products

Patent priority window 2012–2018 Priority dates for asserted Heartflow patents

Patients impacted over 600,000 patients Heartflow Platform usage since 2010

Patent portfolio size over 600 granted patent assets Heartflow worldwide intellectual property portfolio

Development start 2010 Start of development of the Heartflow Platform

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 18	Earnings results	Positive	+1.6%	Reported strong Q4 and FY25 growth with high gross margins and upbeat guidance.
Mar 16	Clinical evidence	Positive	+3.3%	Released large CAD evidence sets and launched NAVIGATE-PCI registry for CT-guided PCI.
Feb 18	Conference appearance	Neutral	+1.3%	Announced participation in a Morgan Stanley TMT conference fireside chat and webcast.
Feb 13	Earnings date set	Neutral	+7.8%	Scheduled Q4 and FY25 earnings release and call with webcast access details.
Feb 12	Registry expansion	Positive	-16.6%	Expanded GAMEFILM registry to NBA and NHL alumni using AI-powered plaque analysis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historically, HTFL has shown mostly positive alignment between news and price, with one notable selloff on otherwise constructive product/registry news.

Recent Company History

Over the last few months, HTFL has focused on growth and evidence-building. Earnings on Mar 18 showed strong revenue expansion and high gross margins with constructive guidance. Prior news highlighted large clinical datasets, a new NAVIGATE-PCI registry, and expansion of the GAMEFILM registry into additional professional athlete groups. Investor reactions were generally positive, except for a sharp decline after the GAMEFILM expansion, indicating occasional divergence even on favorable clinical or adoption updates.

Key Terms

patent infringement, permanent injunctive relief, intellectual property, coronary artery disease, +2 more

6 terms

patent infringement regulatory

"announced that it has filed a patent infringement lawsuit against Cleerly, Inc."

Patent infringement occurs when someone makes, uses, sells or imports a product or process that is covered by another party’s patent without permission — like copying a chef’s secret recipe and selling the dish without consent. For investors it matters because alleged infringement can trigger costly lawsuits, damage awards, sales bans or forced licensing, any of which can reduce revenue, increase expenses and hurt a company’s stock value.

permanent injunctive relief regulatory

"The complaint seeks permanent injunctive relief and damages arising from Cleerly’s"

Permanent injunctive relief is a court order that permanently tells a person or company to stop a specific action or to take certain steps, much like a long-term rule imposed after a trial. For investors, it matters because it can force changes to business practices, block sales or products, or require ongoing oversight, potentially affecting revenue, costs, competitive position and the value of a company’s stock.

intellectual property regulatory

"We take seriously our responsibility to protect the intellectual property that supports"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

coronary artery disease medical

"AI technology for coronary artery disease (CAD), today announced that it has filed"

Coronary artery disease is a condition in which the blood vessels that supply the heart become narrowed or blocked by fatty buildup, reducing oxygen-rich blood flow and making the heart work harder. For investors, it matters because the condition drives demand for medications, medical devices, diagnostics and procedures, can affect healthcare spending and payer policies, and influences the financial prospects of companies involved in cardiovascular care—similar to how a clogged pipe changes maintenance and replacement needs.

ischemia medical

"asserts that Cleerly’s Ischemia, Plaque Analysis, and Compare products infringe"

Ischemia is a condition where part of the body isn’t getting enough blood and therefore not enough oxygen and nutrients, like a plant wilting when its water supply is pinched off. For investors, ischemia matters because it drives demand for diagnostics, medications, medical devices and procedures, affects clinical trial outcomes and regulatory decisions, and can influence healthcare costs, liability risk and revenue forecasts for companies in the medical sector.

plaque analysis medical

"asserts that Cleerly’s Ischemia, Plaque Analysis, and Compare products infringe"

Plaque analysis is the medical assessment of fatty or calcified deposits that build up inside blood vessels, usually done with imaging and software to measure size, composition and how likely a blockage or rupture is. Investors care because those results drive demand and regulatory approval for drugs, devices and diagnostic tools, affect clinical trial success rates, and act like an inspection report on a company’s market potential in cardiovascular care.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform

MOUNTAIN VIEW, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed a patent infringement lawsuit against Cleerly, Inc. in the United States District Court for the Eastern District of Texas. The complaint seeks permanent injunctive relief and damages arising from Cleerly’s unauthorized and continued use of Heartflow’s patented technology. Heartflow asserts that Cleerly’s Ischemia, Plaque Analysis, and Compare products infringe six of Heartflow’s patents with priority dates from 2012 to 2018, protecting Heartflow innovations developed years before the introduction of any Cleerly product. The filed complaint can be accessed on Heartflow’s website here.

"Heartflow pioneered a significant medical technology that has touched over 600,000 patients' lives. Our team has worked tirelessly since 2010 to develop the Heartflow Platform, a first-of-its-kind AI solution that has been used to detect and manage coronary artery disease," said John Farquhar, CEO of Heartflow. "We take seriously our responsibility to protect the intellectual property that supports this field and the clinicians and patients it serves."

Heartflow maintains a robust intellectual property portfolio comprising over 600 granted patent assets worldwide. The Company remains focused on advancing its platform and expanding access to precise, non-invasive cardiovascular care.

About Heartflow’s Technology and Research
Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 600,000 patients worldwide.¹ Key benefits include:

• Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
• Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
• Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
• Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.

About Heartflow, Inc.
Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Media Contact
Elliot Levy
elevy@heartflow.com

Investor Contact
Nick Laudico
nlaudico@heartflow.com

_______________________

¹ Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol.